Actinogen Medical has entered 'database lock' for its XanaMIA Alzheimer's trial, finalizing data collection from 247 patients to analyze the effects of its drug Xanamem. The 36-week trial tested Xanamem's ability to slow Alzheimer's progression by controlling brain cortisol levels, targeting patients with elevated pTau181, a marker of disease severity. Results are expected in mid-November and could validate brain cortisol control as a key treatment approach. Actinogen is also running extended and related trials to assess long-term safety and cognitive benefits of Xanamem.
Actinogen Medical's XanaMIA Alzheimer's trial data lock is noted here with Pluang's Health-sector market context as of Oct 21, 2026 08:02 WIB: out of 150 priced Health-sector US stocks, 132 rose and 18 fell today. Notable movers include NUVB at USD 4.84 with an 8.04% increase and a typical hold time of 12 days, TDOC at USD 6.19 rising 8.03% despite a 99% sell order activity and a 39-day hold time, and RVMD at USD 196.55 up 7.91% with a 5-day hold time. The most notable figure is the 132 stocks that advanced in the sector.
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Auna's preliminary Q3 results reveal an 11.7% year-over-year increase in surgeries across Peru, Colombia, and Mexico, driven by higher hospital occupancy and expanded oncology services. Contractual price adjustments also support expectations for EBIT...
Closed-end funds can trade at prices significantly different from their net asset value, creating opportunities for investors to buy at discounts. This article highlights two such funds that provide unique investment exposure and may see their discou...
Canton Coin (CC) dropped 16% over seven days, closing near $0.10 on Oct. 20, down from $0.125 on Oct. 13. This decline comes as The Depository Trust Company (DTC) prepares to launch a tokenization service linked to the Canton Network, expected in Q4 ...
